Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Ward Knutson who wrote (7218)	11/22/1999 3:16:00 AM
From: scaram(o)uche	Read Replies (2) \| Respond to of 9719

Ward: >> You don't comprehend how strong the models were for this drug << I read the manuscripts, and I've worked with similar models. Don't know what more I could do to "comprehend". >> When booking 90% plus GPM and growing revenues at 40%, funny but a significant portion falls to available cash. << Not enough to conduct multi-center phase III trials sufficient to target worldwide registration for multiple indications. That's what V1 was saying when you rudely indicated that he was wrong. You're talking, in the context of V1's point, about peanuts dropping to the bottom line. At the same time, you're representing us as uninformed. >> It is quite obvious to me that you are not in tune with what is an exciting and strong trend being built by HMAF << It's "quite obvious" that you can't tolerate anyone who wants to present a balanced discussion, not even a MOGN bull. MOGN does not have, as V1 indicated, the resources required to take 114 forward alone. Calling "Bob" won't change that. If they attempt to do such, it is a clear indication that they could not license the product under reasonable terms and that competitive projects will move more rapidly through the clinic. The alternative, of course, would be a dilutive move, or a series of dilutive moves, to raise the needed cash. >> You are incredibly mistaken if you think this company has a self-promotion problem. << I've never indicated that they do. I consider it a mistake to have discussed at 47% reduction of tumor burden in a release. >> Blitzer knows MGI Pharma better than yourself......... you don't know what Chuck Blitzer knows. << True! But, what part of this statement didn't you understand..... I still hold some MOGN >> and yet you portray yourself as some type of authority figure << I portray myself as someone who has judged the potential of this company accurately, and as someone who made the CORRECT call regarding Blitzer's '97 Europe BS. Flash back to the summer of 1997. Blitzer had indicated that a european licensing deal was imminent. He also indicated that he would not give away any rights in North America and that support would be sufficient for worldwide development. Miljenko and I clearly said "no way". When he couldn't deliver on his promise, Blitzer didn't step up to say "I was full of it, let's go on.... the company is strong, and I have other options". I'm glad that the company did have the option to continue alone. But, to address your criticism..... I challenged Blitzer on one point, and I was correct. I've now challenged you on one point (MOGN having sufficient resources to proceed alone with phase III), and I'm correct again.